US 9732385B2
· Barken et al.
· 2017
[cited by applicant]
US 20100190162A1
· Rotter et al.
· 2010
[cited by applicant]
US 20100240043A1
· Rotter et al.
· 2010
[cited by applicant]
US 20110177502A1
· Hakonarson et al.
· 2011
[cited by applicant]
US 20140045276A1
· Singh et al.
· 2014
[cited by applicant]
US 20140170157A1
· Agarwal et al.
· 2014
[cited by applicant]
US 20160090629A1
· McGovern
· 2016
[cited by applicant]
US 20170166967A1
· Rotter et al.
· 2017
[cited by applicant]
US 20190211400A1
· Rotter et al.
· 2019
[cited by applicant]
AU 2012254150A1
· 2013
[cited by applicant]
AU 2012254150B2
· 2015
[cited by applicant]
CA 2827609A1
· 2012
[cited by applicant]
CA 2841416A1
· 2012
[cited by applicant]
DK 2676137T3
· 2015
[cited by applicant]
EP 2565277A1
· 2013
[cited by applicant]
EP 2676137B1
· 2014
[cited by applicant]
EP 2997165A2
· 2016
[cited by applicant]
ES 2530175T3
· 2015
[cited by applicant]
IL 227853A
· 2017
[cited by applicant]
KR 20160009582A
· 2016
[cited by applicant]
MX 343327B
· 2016
[cited by applicant]
WO WO2008106451A2
· 2008
[cited by applicant]
WO WO2008106451A3
· 2008
[cited by applicant]
WO WO2009052512A2
· 2009
[cited by applicant]
WO WO2009105590A2
· 2009
[cited by applicant]
WO WO2009105590A3
· 2010
[cited by applicant]
WO WO2012154253A1
· 2012
[cited by applicant]
WO WO2012174338A2
· 2012
[cited by applicant]
WO WO2013059732A1
· 2013
[cited by applicant]
WO WO2014186750A2
· 2014
[cited by applicant]
WO WO2017106383A1
· 2017
[cited by applicant]
WO WO2017161342A1
· 2017
[cited by applicant]
Aiba et al., The role of TL1A and DR3 in autoimmune and inflammatory diseases. Mediators Inflamm. 2013:#258164, 9 pages.
[cited by applicant]
Chinese Patent Application No. 201480038133.6 Second Office Action dated Jan. 21, 2019.
[cited by applicant]
European Patent Application No. 14797214 Extended European Search Report dated Feb. 3, 2017, 15 pages.
[cited by applicant]
European Patent Application No. 14797214 Partial European Search Report dated Oct. 28, 2016, 9 pages.
[cited by applicant]
European Patent Application No. 17767679.8 Supplementary European Search Report dated Jul. 22, 2019.
[cited by applicant]
European Patent Application No. 18201967.9 European Search Report dated Mar. 6, 2019.
[cited by applicant]
Fransen et al., Inflammatory bowel disease: the genetic background and beyond. University of Groningen PhD Dissertation http://www.rug.nl/research/portal/files/12805965/Complete_dissertation.pdf (2014).
[cited by applicant]
Fuliang et al.: Diagnostics and Therapeutics of Digestive System Diseases. Scientific and Technical Literature Publishing House. 309-310 (2004).
[cited by applicant]
Haritunians et al., Genetic Predictors of Medically Refractory Ulcerative Colitis, Inflamm Bowel Dis., 2010, vol. 16 ;11), pp. 1830-1840.
[cited by applicant]
Hirano et al., Association Study of 71 European Crohn's Disease Susceptibility Loci in a Japanese Population, Inflammatory Bowel Diseases, 19(3):526-533, 2013.
[cited by applicant]
Japanese Patent Application No. 2016-514143 Office Action dated Apr. 2, 2018.
[cited by applicant]
Jostins et al.: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature; 491/7422:119-124 (2012).
[cited by applicant]
Jung et al., Genotype/Phenotype analyses for 53 Crohn's disease associated genetic polymorphisms. PLOS/One, 7(12):e52223, 2012.
[cited by applicant]
Kakuta et al., Su1746 Rare Variants of TNFSF15 are Significantly Associated With Crohn's Disease in Non-Jewish Caucasian Independent of the Known Common Susceptibility SNPs, Gastroenterology, 144(5): S-466, 2013.
[cited by applicant]
Kugathansan et al., Loci on 20q13 and 21q22 are associated with pediatric onset inflammatory bowel disease. Nature Genetics 40:1211-1215 (2008).
[cited by applicant]
Mcgovern et al., Genetics of inflammatory bowel diseases. Gastroenterology 149(5):1163-1176 (2015).
[cited by applicant]
Michelsen et al., IBD-Associated TL 1A Gene (TNFSF15) Haplotypes Determine Increased Expression of TL 1A Protein. PLoS ONE. 4:e4719 (2009).
[cited by applicant]
PCT/US2008/055020 International Search Report and Written Opinion dated Aug. 14, 2008, 8 pages.
[cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Feb. 19, 2021 (246 pages).
[cited by applicant]
Picornell et al., TNFSF15 is an ethnic specific IBD gene. Inflamm. Bowel Disease, 13(11):1333-1338, 2007.
[cited by applicant]
Takedatsu et al.: TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating both T helper (TH) 1 and TH17 Activation; Gastroenterology; HHS Public Access; 135(2): 552-567 (2008).
[cited by applicant]
Tong Ren Tang Health Center Editorial Board: Fruity Health Care Dictionary; p. 153 (Jan. 31, 2013).
[cited by applicant]
Tremelling et al., Contribution of TNFSF15 Gene Variants to Crohn's Disease Susceptibility Confirmed in UK Population, Inflammatory Bowel Diseases, 14(6):733-737, 2008.
[cited by applicant]
Wen et al., TL 1A-induced NF-kB activation and c-IAP2 production prevent DR3-mediated C456 apoptosis in TF-1 cells. J Biol Chem 278:39251-39258 (2003).
[cited by applicant]
Yamazaki et al., Single nucleotide polymorphisms in TNFSF15 confers susceptibility to Crohn's disease. Hum Mol Genet 14:3499-3506 (2005).
[cited by applicant]
Yang, Suk-Kyun et al., Association of TNFSF15 with Crohn's Disease in Koreans, American Journal of Gastroenterology 2008;103:1437-1442.
[cited by applicant]